223 related articles for article (PubMed ID: 29574067)
1. Structure-kinetic relationship studies of cannabinoid CB
Soethoudt M; Hoorens MWH; Doelman W; Martella A; van der Stelt M; Heitman LH
Biochem Pharmacol; 2018 Jun; 152():129-142. PubMed ID: 29574067
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.
Yrjölä S; Sarparanta M; Airaksinen AJ; Hytti M; Kauppinen A; Pasonen-Seppänen S; Adinolfi B; Nieri P; Manera C; Keinänen O; Poso A; Nevalainen TJ; Parkkari T
Eur J Pharm Sci; 2015 Jan; 67():85-96. PubMed ID: 25447744
[TBL] [Abstract][Full Text] [Related]
3. New Pyridone-Based Derivatives as Cannabinoid Receptor Type 2 Agonists.
Faúndez-Parraguez M; Alarcón-Miranda C; Cho YH; Pessoa-Mahana H; Gallardo-Garrido C; Chung H; Faúndez M; Pessoa-Mahana D
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681877
[TBL] [Abstract][Full Text] [Related]
4. Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis.
Porter RF; Szczesniak AM; Toguri JT; Gebremeskel S; Johnston B; Lehmann C; Fingerle J; Rothenhäusler B; Perret C; Rogers-Evans M; Kimbara A; Nettekoven M; Guba W; Grether U; Ullmer C; Kelly MEM
Molecules; 2019 Sep; 24(18):. PubMed ID: 31540271
[TBL] [Abstract][Full Text] [Related]
5. The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity.
Mukhopadhyay P; Baggelaar M; Erdelyi K; Cao Z; Cinar R; Fezza F; Ignatowska-Janlowska B; Wilkerson J; van Gils N; Hansen T; Ruben M; Soethoudt M; Heitman L; Kunos G; Maccarrone M; Lichtman A; Pacher P; Van der Stelt M
Br J Pharmacol; 2016 Feb; 173(3):446-58. PubMed ID: 26398481
[TBL] [Abstract][Full Text] [Related]
6. The discovery of a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine cannabinoid type 2 receptor agonist.
Moir M; Lane S; Montgomery AP; Hibbs D; Connor M; Kassiou M
Eur J Med Chem; 2021 Jan; 210():113087. PubMed ID: 33321261
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of imidazothiazinones and analogs as antagonists of the cannabinoid-activated orphan G protein-coupled receptor GPR18.
Schoeder CT; Kaleta M; Mahardhika AB; Olejarz-Maciej A; Łażewska D; Kieć-Kononowicz K; Müller CE
Eur J Med Chem; 2018 Jul; 155():381-397. PubMed ID: 29902723
[TBL] [Abstract][Full Text] [Related]
8. Latest progress in the identification of novel synthetic ligands for the cannabinoid CB2 receptor.
Han S; Chen JJ; Chen JZ
Mini Rev Med Chem; 2014 May; 14(5):426-43. PubMed ID: 24766386
[TBL] [Abstract][Full Text] [Related]
9. Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects.
Hu SJ; Cheng G; Zhou H; Zhang Q; Zhang QL; Wang Y; Shen Y; Lian CX; Ma XQ; Zhang QY; Qin LP
Molecules; 2022 Jan; 27(3):. PubMed ID: 35163968
[TBL] [Abstract][Full Text] [Related]
10. New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking.
Ragusa G; Gómez-Cañas M; Morales P; Rodríguez-Cueto C; Pazos MR; Asproni B; Cichero E; Fossa P; Pinna GA; Jagerovic N; Fernández-Ruiz J; Murineddu G
Eur J Med Chem; 2017 Feb; 127():398-412. PubMed ID: 28088085
[TBL] [Abstract][Full Text] [Related]
11. Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists.
Gianella-Borradori M; Christou I; Bataille CJ; Cross RL; Wynne GM; Greaves DR; Russell AJ
Bioorg Med Chem; 2015 Jan; 23(1):241-63. PubMed ID: 25487422
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of oxidative metabolites of CRA13 and their analogs: Identification of CRA13 active metabolites and analogs thereof with selective CB
Hassan AHE; Cho MC; Kim HI; Yang JS; Park KT; Hwang JY; Jang CG; Park KD; Lee YS
Bioorg Med Chem; 2018 Oct; 26(18):5069-5078. PubMed ID: 30217464
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of selective cannabinoid CB
Li X; Chang H; Bouma J; de Paus LV; Mukhopadhyay P; Paloczi J; Mustafa M; van der Horst C; Kumar SS; Wu L; Yu Y; van den Berg RJBHN; Janssen APA; Lichtman A; Liu ZJ; Pacher P; van der Stelt M; Heitman LH; Hua T
Nat Commun; 2023 Mar; 14(1):1447. PubMed ID: 36922494
[TBL] [Abstract][Full Text] [Related]
14. A Novel Selective Inverse Agonist of the CB
Martella A; Sijben H; Rufer AC; Grether U; Fingerle J; Ullmer C; Hartung T; IJzerman AP; van der Stelt M; Heitman LH
Mol Pharmacol; 2017 Oct; 92(4):389-400. PubMed ID: 28747489
[TBL] [Abstract][Full Text] [Related]
15. Novel Cannabinoid Receptor 2 (CB2) Low Lipophilicity Agonists Produce Distinct cAMP and Arrestin Signalling Kinetics without Bias.
Sharma R; Singh S; Whiting ZM; Molitor M; Vernall AJ; Grimsey NL
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047385
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, and Physicochemical and Pharmacological Profiling of 7-Hydroxy-5-oxopyrazolo[4,3-
Mugnaini C; Kostrzewa M; Bryk M; Mahmoud AM; Brizzi A; Lamponi S; Giorgi G; Ferlenghi F; Vacondio F; Maccioni P; Colombo G; Mor M; Starowicz K; Di Marzo V; Ligresti A; Corelli F
J Med Chem; 2020 Jul; 63(13):7369-7391. PubMed ID: 32515588
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease.
González-Naranjo P; Pérez-Macias N; Campillo NE; Pérez C; Arán VJ; Girón R; Sánchez-Robles E; Martín MI; Gómez-Cañas M; García-Arencibia M; Fernández-Ruiz J; Páez JA
Eur J Med Chem; 2014 Feb; 73():56-72. PubMed ID: 24378710
[TBL] [Abstract][Full Text] [Related]
18. Novel Triazolopyrimidine-Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney Diseases.
Nettekoven M; Adam JM; Bendels S; Bissantz C; Fingerle J; Grether U; Grüner S; Guba W; Kimbara A; Ottaviani G; Püllmann B; Rogers-Evans M; Röver S; Rothenhäusler B; Schmitt S; Schuler F; Schulz-Gasch T; Ullmer C
ChemMedChem; 2016 Jan; 11(2):179-89. PubMed ID: 26228928
[TBL] [Abstract][Full Text] [Related]
19. Dual allosteric and orthosteric pharmacology of synthetic analog cannabidiol-dimethylheptyl, but not cannabidiol, on the cannabinoid CB
Bouma J; Broekhuis JD; van der Horst C; Kumar P; Ligresti A; van der Stelt M; Heitman LH
Biochem Pharmacol; 2023 Dec; 218():115924. PubMed ID: 37972874
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid CB
Soethoudt M; Grether U; Fingerle J; Grim TW; Fezza F; de Petrocellis L; Ullmer C; Rothenhäusler B; Perret C; van Gils N; Finlay D; MacDonald C; Chicca A; Gens MD; Stuart J; de Vries H; Mastrangelo N; Xia L; Alachouzos G; Baggelaar MP; Martella A; Mock ED; Deng H; Heitman LH; Connor M; Di Marzo V; Gertsch J; Lichtman AH; Maccarrone M; Pacher P; Glass M; van der Stelt M
Nat Commun; 2017 Jan; 8():13958. PubMed ID: 28045021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
